Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Dirk, Klingbiel"'
Autor:
Miguel A. Canales, Thomas A. Buchholz, Jaisson A.P. Bortolini, Laura M. Fogliatto, Takayuki Ishikawa, Koji Izutsu, Antonio Salar, Jeff P. Sharman, Dirk Klingbiel, Sunny Pokala, Ekaterina Vorozheikina, Peter Trask, Joana Parreira, Kai Hübel
Publikováno v:
HemaSphere, Vol 7, Iss 4, p e860 (2023)
Externí odkaz:
https://doaj.org/article/d7f09369c3394dc7bc1595f8a3af8bcc
Autor:
Serenella Eppenberger-Castori, Dirk Klingbiel, Thomas Ruhstaller, Daniel Dietrich, Daniel Alexander Rufle, Karin Rothgiesser, Olivia Pagani, Beat Thürlimann
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The HER2 extracellular domain shed in blood (HER2ECD) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2ECD values in patients with metasta
Externí odkaz:
https://doaj.org/article/3e2f1998662b4126856dd5c1de79bb5b
Autor:
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 2
Externí odkaz:
https://doaj.org/article/3a71b23e5f6e4fdeb49b83bd63c454c7
Publikováno v:
Clinical Cancer Research. 29:1468-1476
Purpose: In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b342b1b5d42522c7db8f6908ac6d36c
https://doi.org/10.1158/1078-0432.ccr-22-1092
https://doi.org/10.1158/1078-0432.ccr-22-1092
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-13 (2017)
Abstract Background The SAKK 19/05 trial investigated the safety and efficacy of the combined targeted therapy bevacizumab and erlotinib (BE) in unselected patients with advanced non-squamous non-small cell lung cancer (NSCLC). Although activating EG
Externí odkaz:
https://doaj.org/article/61dbf79f0895467c8ab18614ce1b0573
Autor:
Darius Juskevicius, David Jucker, Dirk Klingbiel, Christoph Mamot, Stephan Dirnhofer, Alexandar Tzankov
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-10 (2017)
Abstract Background/purpose Recently, the mutational background of diffuse large B cell lymphoma (DLBCL) has been revealed, identifying specific genetic events that drive lymphomagenesis. However, the prognostic value of these mutations remains to be
Externí odkaz:
https://doaj.org/article/f783188417e3474e953a6efd0599eec5
Autor:
Mothaffar F. Rimawi, Raf Poppe, Christine Wohlfarth, Valentine Revelant, Dirk Klingbiel, C. Kent Osborne, Sabino De Placido, Jean-Marc Ferrero, Juan de la Haba Rodríguez, Grazia Arpino
Investigator list and Supplementary Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7a7da8da56b23d9af0a541f6194ad9
https://doi.org/10.1158/1078-0432.22633063.v1
https://doi.org/10.1158/1078-0432.22633063.v1
Autor:
Mothaffar F. Rimawi, Raf Poppe, Christine Wohlfarth, Valentine Revelant, Dirk Klingbiel, C. Kent Osborne, Sabino De Placido, Jean-Marc Ferrero, Juan de la Haba Rodríguez, Grazia Arpino
Purpose:In PERTAIN's primary analysis (31 months’ median follow-up), adding pertuzumab to trastuzumab and an aromatase inhibitor (AI) with/without chemotherapy significantly improved progression-free survival (PFS) in patients with previously untre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c31f393b926d6f08d7c60c2f0042e0
https://doi.org/10.1158/1078-0432.c.6533152
https://doi.org/10.1158/1078-0432.c.6533152
Autor:
Roberto Fiocca, Fredrik T. Bosman, Mauro Delorenzi, Sabine Tejpar, Arnaud Roth, Thomas Alexander McKee, Monica Curto, Paola Ceppa, Zenia Saridaki, Dirk Klingbiel, Pu Yan
Legends for supplementary figures 1 and 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4d2a841ddf396a48f8cd8ffc3b4f3d
https://doi.org/10.1158/1078-0432.22459376
https://doi.org/10.1158/1078-0432.22459376
Autor:
Martin H. Brutsche, Francesco Zappa, Dirk Klingbiel, Bogdan D. Grigoriu, Daniel Betticher, Cornelia Droege, Oliver Dürr, Ina I. Macovei, Florent Baty, Anca Franzini
Supplementary Tables 1-3, Figures 1-6. Supplementary Table 1: Statistical analysis of differences between the study group and the remaining group of patients for several variables. Supplementary Table 2: Primers used for the RT-qPCR assays. Supplemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31bd2b21ad1a4b111d6e71f4b5ef858
https://doi.org/10.1158/1078-0432.22460262
https://doi.org/10.1158/1078-0432.22460262